Haplotype structures of common variants of CYP2C8, CYP2C9, and ADRB1 genes in a South Indian population

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 6, 2011, Pages 407-413

  Arun Kumar, Annan Sudarsan ^a   Chakradhara Rao, Uppugunduri Satyanarayana ^a   Umamaheswaran, Gurusamy ^a   Ramu, Periyasamy ^a   Kesavan, Ramasamy ^a   Shewade, Deepak Gopal ^a   Balachandar, Jayaraman ^a   Adithan, Chandrasekaran ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9;

ADULT; AFRICA; ALLELE; ARTICLE; CHINESE; CHROMOSOME 10; ETHNIC DIFFERENCE; ETHNIC GROUP; EUROPE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENETIC ASSOCIATION; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INDIA; JAPANESE; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ARYL HYDROCARBON HYDROXYLASES; ETHNIC GROUPS; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; INDIA; LINKAGE DISEQUILIBRIUM; RECEPTORS, ADRENERGIC, BETA-1;

EID: 79959275244     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0170     Document Type: Article

References (27)

1. Adithan C, Gerard N, Vasu S, et al. (2003) Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol 59:707-709. (Pubitemid 37498209)
2. Aithal GP, Day CP, Kesteven PJ, et al. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719. (Pubitemid 29103806)
3. Altshuler D, Brooks LD, Chakravarti A, et al. (2005) A haplotype map of human genome. Nature 437:1299-1320.
4. Barrett JC, Fry B, Maller J, et al. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265. (Pubitemid 40202029)
5. Beitelshees AL, Zineh I, Yarandi HN, et al. (2006) Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. Pharmacogenomics 6:174-178. (Pubitemid 43811568)
6. Bhasker CR, Miners JO, Coulter S, et al. (1997) Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 7:51-58. (Pubitemid 27153319)
7. Bruck H, Leineweber K, Temme T, et al. (2005) The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol 46:2111-2115. (Pubitemid 41713600)
8. Dai D, Zeldin DC, Blaisdell JA, et al. (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607. (Pubitemid 32953585)
9. Daly MJ, Rioux JD, Schaffner SF, et al. (2001) High-resolution haplotype structure in the human genome. Nat Genet 29:229-232. (Pubitemid 32952664)
10. Ellsworth DL, Coady SA, Chen W, et al. (2005) Interactive effects between polymorphisms in the beta-adrenergic receptors and longitudinal changes in obesity. Obes Res 13:519-526.
11. *3 Alleles confer a lower risk for myocardial infarction. Clin Chem 50:2395-2398. (Pubitemid 39552183)
12. Gadgil M, Joshi NV, Manoharan P, et al. (1998) Peopling of India. In: Balasubramanian D, Rao NA (eds) The Indian Human Heritage. Universities Press, Hyderabad, pp 100-129.
13. Gray IC, Nobile C, Muresu R, et al. (1995) A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 28:328-332.
14. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available at www.cypalleles.ki.se/cyp2c8.htm, accessed July 31, 2010.
15. Iwai C, Akita H, Shiga N, et al. (2002) Suppressive effect of the Gly389 allele of the beta1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy. Circ J 66:723-728.
16. King LM, Gainer JV, David GL, et al. (2005) Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics 1:7-13. (Pubitemid 43205521)
17. Lee CR, North KE, Bray MS, et al. (2007) CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the atherosclerosis risk in communities (ARIC) study. Pharmacogenet Genomics 5:349-358. (Pubitemid 46608542)
18. Mahesh Kumar KN, Ramu P, Rajan S, et al. (2008) Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population. J Cardiovasc Pharmacol 52:459-466.
19. Nakajima M, Fujiki Y, Noda K, et al. (2003) Genetic polymorphism of CYP2C8 in Japanese population. Drug Metab Dispos 31:687-690. (Pubitemid 36617652)
20. Nonen S, Okamoto H, Akino M, et al. (2005) No positive association between adrenergic receptor variants of a2cDel322-325, b1Ser49, b1Arg389 and the risk for heart failure in the Japanese population. Br J Clin Pharmacol 60:414-417. (Pubitemid 41428472)
21. Sawyer SL, Mukherjee N, Pakstis AJ, et al. (2005) Linkage disequilibrium patterns vary substantially among populations. Eur J Hum Genet 13:677-686. (Pubitemid 40691410)
22. Speed WC, Kang SP, Tuck DP, et al. (2009) Global variation in CYP2C8-CYP2C9 functional haplotypes. Pharmacogenomics J 9:283-290.
23. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349. (Pubitemid 26288624)
24. Weir BS, Hill WG (1980) Effect of mating structure on variation in LD. Genetics 95:477-488.
25. Yasar U, Bennet AM, Eliasson E, et al. (2003) Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13:715-720. (Pubitemid 38429249)
26. Yasar U, Lundgren S, Eliasson E, et al. (2002) Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299:25-28. (Pubitemid 35366030)
27. Zhou HH, Koshakji RP, Silberstein DJ, et al. (1989) Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 320:565-570. (Pubitemid 19070541)